Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants-Reference-Cited by-同舟云学术

Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants

Published:2016-11-03 Issue:11 Volume:23 Page:2665-2672
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Jethava Yogesh S.,Mitchell Alan,Epstein Joshua,Zangari Maurizio,Yaccoby Shmuel,Tian Erming,Waheed Sarah,Khan Rashid,Papanikolaou Xenofon,Grazziutti Monica,Cottler-Fox Michele,Petty Nathan,Steward Douglas,Panozzo Susan,Bailey Clyde,Hoering Antje,Crowley John,Sawyer Jeffrey,Morgan Gareth,Barlogie Bart,van Rhee Frits

Funder

NCINIHNIH

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of algorithms for identifying patients with triple-class refractory multiple myeloma using real-world data;Current Medical Research and Opinion;2024-04-12

2. In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT;Bone Marrow Transplantation;2024-01-31

3. In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT;2023-09-22

4. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states;Nature Communications;2022-08-03

5. Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions;Frontiers in Immunology;2020-04-24